You are here

Home › Pfizer starts late-stage trial of mRNA-based flu vaccine › Pfizer starts late-stage trial of mRNA-based flu vaccine

Pfizer starts late-stage trial of mRNA-based flu vaccine

Primary tabs

Pfizer starts late-stage trial of mRNA-based flu vaccine

Thu, 2022-09-15 10:19 — mike kraft
Pfizer starts late-stage trial of mRNA-based flu vaccine Pfizer Inc said on Wednesday it had started a late-stage U.S. trial of an influenza vaccine involving 25,000 patients, among the first such studies for a messenger RNA flu shot. Reuters Reuters

...

The company said that the first participants had been dosed with the vaccine, which is based on the same technology used in its widely-used COVID-19 shot developed in partnership with Germanay's BioNTech SE (22UAy.DE).

...

 

Country / Region Tags: 
Germany
Global
United States
General Topic Tags: 
Disease
Disease Prevention
Health
Public Health
Research
Vaccinations
Problem, Solution, SitRep, or ?: 
Situation Report
Groups this Group Post belongs to: 
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks